Posted by 
A recent study from researchers at the Icahn School of Medicine at Mount Sinai provides new insights into a link between inflammatory bowel disease (IBD) and Parkinson’s disease, Individuals with IBD are at a 28% higher risk of developing Parkinson’s disease than those without IBD.
Treating the patients with anti-Tumor Necrosis Factor alpha (anti-TNFα) therapy- a monoclonal antibody that is commonly used to control inflammation in IBD patients, may reduce the risk of developing Parkinson’s disease. IBD onset usually precedes Parkinson’s disease by decades, anti-TNFα therapy may prevent Parkinson’s disease in people suffering from IBD.
Previous research had shown genetic and functional connections between IBD and Parkinson’s disease. Systemic inflammation is a major component of IBD, and it’s also contribute to the neuronal inflammation found in Parkinson’s disease,” explained Inga Peter, Professor in the Department of Genetics and Genomic Sciences at Mount Sinai and lead investigator in the study.
Researchers tested anti-TNFα therapy on participants for the experiment and discovered a78% reduction in the incidence of Parkinson’s disease among IBD patients who were treated with anti-TNFα therapy when compared to those who were not.
haleplushearty.org